St. Jude Medical, Inc. (NYSE:STJ) today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW), in addition to reimbursement approval, of its Atlas® II implantable cardioverter defibrillator (ICD), a device used to treat patients with potentially lethal abnormal heart rhythms. More at...
St. Jude Medical, Inc. (NYSE:STJ) announced the publication of results from the landmark FAME (Fractional flow reserve (FFR) vs. Angiography in Multivessel Evaluation) study that demonstrate a statistically significant 30 percent difference in Major Adverse Cardiac Events (MACE) such as death, myocardial infarction and repeat revascularization. More at...
Phoenix, AZ - Zila Pharmaceuticals, Inc., a division of Zila, Inc. (NASDAQ GM: ZILA) and marketer of the ViziLite® Plus with TBlue® system for the early detection of oral abnormalities that could lead to cancer, has been honored with two awards from Hygienetown, the magazine and web community for dental hygienists. More at...
Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Hansen Medical, Inc. (Nasdaq: HNSN) today announced that they have signed joint development and cooperation agreements to co-develop integrated products that may simplify complex cardiac procedures to diagnose and treat irregular heartbeats, also known as arrhythmias. Cardiac arrhythmias can drastically reduce the quality of life and can also lead to serious health risks including heart failure and stroke. More at...
The first patient receiving focal preventive treatment for vulnerable plaque recently underwent a 6-month follow-up examination that revealed successful stabilization of the target plaque. The interventional cardiology team led by Professor Patrick W. Serruys, MD, PhD, of Erasmus University, placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008. More at...
Hansen Medical, Inc. (NASDAQ: HNSN) will showcase its Sensei(R) Robotic Catheter System and the CoHesion(TM) 3-D Visualization Module here at the 14th Annual Boston Atrial Fibrillation Symposium, Jan. 15-17, 2009. The integrated electrophysiology (EP) solution offers physicians a software interface between Hansen Medical's robotic catheter system and St. Jude Medical's EnSite(TM) System advanced mapping technology. More at...
Friday, January 16, 2009
Thursday, January 15, 2009
Midlife Coffee And Tea Drinking And The Risk Of Late Life Dementia
Midlife Coffee And Tea Drinking And The Risk Of Late Life Dementia
Midlife coffee drinking can decrease the risk of dementia/Alzheimer's disease (AD) later in life. This conclusion is made in a Finnish Cardiovascular Risk Factors, Aging and Dementia (CAIDE) Study published in the January 2009 issue of the Journal of Alzheimer's Disease (Volume 16:1). This study has been conducted at the University of Kuopio, Finland in collaboration with Karolinska Institutet, Stockholm, Sweden, and the National Public Health Institute, Helsinki, Finland.
Lower Risk Of Dementia And Alzheimer's Linked To Midlife Coffee Drinking
Researchers in Finland and Sweden who followed over 1,400 middle-aged people over twenty years, found that those who drank three to five cups of coffee a day in their midlife years were less likely to develop dementia or Alzheimer's disease in old age compared with those who drank either no coffee at all or very little.
Technology With A Personality For Dementia Care
The University of Dundee and Balhousie Care Group have formed a unique partnership to create an innovative use of touchscreens and multimedia to enhance the care of people with dementia. The partnership has created a new PhD Studentship within the School of Computing at the University, building on existing research excellence in developing technology to help older people.
A Weighted Communicability Measure Applied To Complex Brain Networks
New magnetic resonance imaging techniques allow brain maps of live humans to be constructed. So scientists can now investigate how neurological disorders, such as Parkinson's disease, Alzheimer's disease and schizophrenia change the wiring in the brain. Crofts and Higham at the University of Strathclyde looked at brain networks of patients who had suffered strokes. They introduced a new concept called `weighted communicability', which measures the way information spreads around the brain.
Midlife coffee drinking can decrease the risk of dementia/Alzheimer's disease (AD) later in life. This conclusion is made in a Finnish Cardiovascular Risk Factors, Aging and Dementia (CAIDE) Study published in the January 2009 issue of the Journal of Alzheimer's Disease (Volume 16:1). This study has been conducted at the University of Kuopio, Finland in collaboration with Karolinska Institutet, Stockholm, Sweden, and the National Public Health Institute, Helsinki, Finland.
Lower Risk Of Dementia And Alzheimer's Linked To Midlife Coffee Drinking
Researchers in Finland and Sweden who followed over 1,400 middle-aged people over twenty years, found that those who drank three to five cups of coffee a day in their midlife years were less likely to develop dementia or Alzheimer's disease in old age compared with those who drank either no coffee at all or very little.
Technology With A Personality For Dementia Care
The University of Dundee and Balhousie Care Group have formed a unique partnership to create an innovative use of touchscreens and multimedia to enhance the care of people with dementia. The partnership has created a new PhD Studentship within the School of Computing at the University, building on existing research excellence in developing technology to help older people.
A Weighted Communicability Measure Applied To Complex Brain Networks
New magnetic resonance imaging techniques allow brain maps of live humans to be constructed. So scientists can now investigate how neurological disorders, such as Parkinson's disease, Alzheimer's disease and schizophrenia change the wiring in the brain. Crofts and Higham at the University of Strathclyde looked at brain networks of patients who had suffered strokes. They introduced a new concept called `weighted communicability', which measures the way information spreads around the brain.
Wednesday, January 14, 2009
Human Beta Cells Can Be Easily Induced To Replicate, According To Pitt Study In Diabetes
Researchers at the University of Pittsburgh School of Medicine have successfully induced human insulin-producing cells, known as beta cells, to replicate robustly in a living animal, as well as in the lab. The discovery not only could improve models and methods for studying diabetes, but also opens up new possibilities for treating the condition. More at...
Introduced in the 1960s, oral contraceptives have been used by about 80 percent of women in the United States at some point in their lives. More at...
Crucial breakthroughs in the treatment of many common diseases such as diabetes and Parkinson's could be achieved by harnessing a powerful scientific approach called systems biology, according to leading scientists from across Europe. In a Science Policy Briefing released by the European Science Foundation, the scientists provide a detailed strategy for the application of systems biology to medical research over the coming years. More at...
MannKind Corporation (Nasdaq: MNKD) announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra rapid acting insulin that recently completed Phase 3 clinical trials. More at...
A benchmarking study published in the Journal of Hospital Medicine evaluated contemporary hospital glycemic management in United States academic medical centers, determining glucose control practices are suboptimal and do not meet current American Diabetes Association (ADA) hospital diabetes care standards. More at...
A new study from the US found that patients with peripheral arterial disease (PAD), which is sometimes accompanied by pain in leg muscles, improved their walking endurance and quality of life by taking part in a treadmill walking exercise that also helped patients who did not have the classic symptoms of pain in the legs. More at...
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced further results from a Phase 2b clinical trial testing the safety and efficacy of its oral anti-arrhythmic therapy, ATI-2042, in patients with atrial fibrillation. This follows the December 18, 2008 press release reporting that ATI-2042 reached statistical significance at its primary end point in the two highest of three doses tested. More at...
Introduced in the 1960s, oral contraceptives have been used by about 80 percent of women in the United States at some point in their lives. More at...
Crucial breakthroughs in the treatment of many common diseases such as diabetes and Parkinson's could be achieved by harnessing a powerful scientific approach called systems biology, according to leading scientists from across Europe. In a Science Policy Briefing released by the European Science Foundation, the scientists provide a detailed strategy for the application of systems biology to medical research over the coming years. More at...
MannKind Corporation (Nasdaq: MNKD) announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra rapid acting insulin that recently completed Phase 3 clinical trials. More at...
A benchmarking study published in the Journal of Hospital Medicine evaluated contemporary hospital glycemic management in United States academic medical centers, determining glucose control practices are suboptimal and do not meet current American Diabetes Association (ADA) hospital diabetes care standards. More at...
A new study from the US found that patients with peripheral arterial disease (PAD), which is sometimes accompanied by pain in leg muscles, improved their walking endurance and quality of life by taking part in a treadmill walking exercise that also helped patients who did not have the classic symptoms of pain in the legs. More at...
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced further results from a Phase 2b clinical trial testing the safety and efficacy of its oral anti-arrhythmic therapy, ATI-2042, in patients with atrial fibrillation. This follows the December 18, 2008 press release reporting that ATI-2042 reached statistical significance at its primary end point in the two highest of three doses tested. More at...
Subscribe to:
Posts (Atom)
